Search results (139)
« Back to PublicationsIndividual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database.
Journal article
Ali M. et al, (2026), Health Soc Care Deliv Res, 14, 1 - 160
The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH.
Journal article
Srivaths L. et al, (2026), J Thromb Haemost
Thrombin Generation as a Potential Surrogate Marker of Hemostatic Status in the Era of Novel Therapies for Hemophilia.
Journal article
Dargaud Y. et al, (2026), Thromb Haemost
Diagnosis and management of hemophilia A and B.
Journal article
Lim MY. et al, (2026), J Thromb Haemost
Guideline for the management of hepatitis B and C infection and subsequent liver disease surveillance (where indicated) in people with congenital bleeding disorders: A joint guideline from the British Society of Haematology and the British Viral Hepatitis Group.
Journal article
Brown A. et al, (2026), Br J Haematol, 208, 855 - 863
Temporal trends in hospital-recorded pulmonary embolism in England before, during and after the COVID-19 pandemic (2008-2024): a population-based observational study.
Journal article
Zhong X. et al, (2025), Lancet Reg Health Eur, 58
Frailty and frailty syndromes in persons with hemophilia: a review.
Journal article
McKeown W. et al, (2025), J Thromb Haemost, 23, 3409 - 3423
Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' Organisation.
Journal article
Wall C. et al, (2025), Res Pract Thromb Haemost, 9
Same-day emergency care: a retrospective observational study of the incidence and predictors of venous thromboembolism following hospital-based acute ambulatory medical care.
Journal article
Shapiro S. et al, (2025), J Thromb Haemost, 23, 97 - 107
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults.
Journal article
Chowdary P. et al, (2025), Haemophilia, 31, 26 - 38
Prevention and management of venous thromboembolism
Chapter
Curry N. and Shapiro S., (2025), 921 - 931
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
Journal article
Madan B. et al, (2024), J Thromb Haemost, 22, 1880 - 1893
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).
Journal article
Fischer K. et al, (2024), Res Pract Thromb Haemost, 8
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Journal article
Mitchell JL. et al, (2023), Platelets, 34
Frailty and haemophilia; speaking the language of geriatricians.
Journal article
Sangha G. et al, (2023), Haemophilia, 29, 1371 - 1375
